Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Tivic Health Systems, Inc. (TIVC)
USD0.43
-0.04 (-8.78%)
US NASDAQ Healthcare Medical - Devices
Address
47685 Lakeview Blvd. 94538
Fremont, CA, US
Fremont, CA, US
CEO
Michael Kevin Handley
Website
tivichealth.com
IPO
2021-11-11
CIK 1787740 ISIN US8887053085
Description
Tivic Health Systems, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offers CDMO services. The company was incorporated in 2016 and is based in San Antonio, Texas.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.43
-0.04 (-8.78%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
262.6K
Beta
1.84
Float Shares
1.03M
Free Float %
95.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -10.81% | -8.84% | -20.00% | -4.54% | -56.92% | -45.93% | -80.97% | -99.57% | -99.99% | -99.99% | -99.99% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.43
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-3.00
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%-51.0% Q1'26: -100.0% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+60.1% ★ Q1'26: +11.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-1,974.1%
-
EBIT margin Medical - Devices: +6.2%-2,054.2%
-
ROIC Medical - Devices: +3.3%-74.0% Q1'26: -161.2% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%-99.9% ★ Q1'26: +383.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.82× Q1'26: -0.45× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|
| Revenue |
1.84M
est: 2.08M (-11.5%)
|
1.18M
est: 3.12M (-62.3%)
|
780.0K
est: 4.89M (-84.0%)
|
382.0K
est: 8.03M (-95.2%)
|
| EBITDA |
-9.92M
est: -2.08M (-377.1%)
|
-8.06M
est: -3.12M (-158.4%)
|
-5.31M
est: -4.89M (-8.6%)
|
-7.84M
est: -8.03M (+2.4%)
|
| EBIT |
-10.10M
est: -2.08M (-385.5%)
|
-8.25M
est: -3.12M (-164.3%)
|
-5.66M
est: -4.89M (-15.8%)
|
-7.85M
est: -8.03M (+2.3%)
|
| Net Income |
-10.10M
est: -547.15B (+100.0%)
|
-8.24M
est: -161.21B (+100.0%)
|
-5.66M
est: -117.25M (+95.2%)
|
-8.88M
|
| SGA |
8.67M
est: 9.48M (-8.6%)
|
6.88M
est: 14.23M (-51.7%)
|
4.35M
est: 31.86M (-86.3%)
|
4.77M
est: 52.34M (-90.9%)
|
| EPS |
-104.37
est: -1,904.00 (+94.5%)
|
-176.72
est: -561.00 (+68.5%)
|
-19.67
est: -408.00 (+95.2%)
|
-7.84
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-11.38M
OE per share TTM
-13.90
Owner's Yield
-452.74%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
28.2%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
9
Total invested
233.4K
Insider transactions (90d)
0
Beneficial owners (>5%)
13
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | L1 Capital Global Opportunities Master Fund Ltd. | 6.00M | 9.60% | 6.00M | — | — | — | FI | Cayman Islands | 2023-07-17 | ↗ |
| 2 | Michael Bigger | 2.10M | 7.10% | — | — | — | 2.10M | IN | Delaware | 2023-02-21 | ↗ |
| 3 | Jennifer Ernst | 1.42M | 14.30% | 1.42M | — | 1.42M | — | IN | United States | 2022-02-14 | ↗ |
| 4 | John Claude | 1.20M | 12.30% | 1.20M | — | 1.20M | — | IN | United States | 2022-02-14 | ↗ |
| 5 | Bigger Capital Fund GP, LLC | 1.10M | 3.70% | — | — | — | 1.10M | OO | Delaware | 2023-02-21 | ↗ |
| 6 | Bigger Capital Fund, LP | 1.10M | 3.70% | — | — | — | 1.10M | PN | Delaware | 2023-02-21 | ↗ |
| 7 | District 2 Capital Fund LP | 1.00M | 3.40% | — | — | — | 1.00M | PN | Delaware | 2023-02-21 | ↗ |
| 8 | District 2 Capital LP | 1.00M | 3.40% | — | — | — | 1.00M | PN | Delaware | 2023-02-21 | ↗ |
| 9 | District 2 GP LLC | 1.00M | 3.40% | — | — | — | 1.00M | OO | Delaware | 2023-02-21 | ↗ |
| 10 | District 2 Holdings LLC | 1.00M | 3.40% | — | — | — | 1.00M | OO | Delaware | 2023-02-21 | ↗ |
| 11 | Daniel B. Asher | 324.8K | 4.99% | — | 324.8K | — | 324.8K | HC, IN | United States of America | 2024-05-15 | ↗ |
| 12 | Intracoastal Capital LLC | 324.8K | 4.99% | — | 324.8K | — | 324.8K | OO | United States of America | 2024-05-15 | ↗ |
| 13 | Mitchell P. Kopin | 324.8K | 4.99% | — | 324.8K | — | 324.8K | HC, IN | United States of America | 2024-05-15 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
9
+2 vs prev Q
New positions
5
Closed positions
3
Increased
6
Reduced
2
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT, LLC | 87.8K +87.8K (+100.0%) | 77.8K +77.8K (+100.0%) | 3.05% +3.045 pp | 0.00% +0.000 pp | USD0.89 +0.0% | 1 qtrs NEW |
| 2 | SANCTUARY ADVISORS, LLC | 61.2K +61.2K (+100.0%) | 54.2K +54.2K (+100.0%) | 2.12% +2.123 pp | 0.00% +0.000 pp | USD0.89 +0.0% | 1 qtrs NEW |
| 3 | MAREX GROUP PLC | 59.3K +18.3K (+44.7%) | 52.5K -6.9K (-11.6%) | 2.06% +0.635 pp | 0.00% +0.000 pp | USD3.02 -70.5% | 4 qtrs — |
| 4 | HRT FINANCIAL LP | 42.4K +42.4K (+100.0%) | 37.0K +37.0K (+100.0%) | 1.47% +1.471 pp | 0.00% +0.000 pp | USD0.89 +0.0% | 1 qtrs NEW |
| 5 | XTX TOPCO LTD | 10.5K +10.5K (+100.0%) | 9.3K +9.3K (+100.0%) | 0.36% +0.364 pp | 0.00% +0.000 pp | USD0.89 +0.0% | 1 qtrs NEW |
| 6 | UBS GROUP AG | 2.4K -17.3K (-88.0%) | 2.1K -26.4K (-92.6%) | 0.08% -0.600 pp | 0.00% +0.000 pp | USD1.56 -42.9% | 4 qtrs — |
| 7 | TOWER RESEARCH CAPITAL LLC (TRC) | 584.00 -1.1K (-64.6%) | 517.00 -1.9K (-78.4%) | 0.02% -0.037 pp | 0.00% +0.000 pp | USD1.45 -38.6% | 2 qtrs — |
| 8 | SBI SECURITIES CO., LTD. | 16.00 +— (+0.0%) | 14.00 -9.0 (-39.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.50 -64.4% | 5 qtrs — |
| 9 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 1.00 +1.0 (+100.0%) | 1.00 +1.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 1 qtrs NEW |
| 10 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | — -14.6K (-100.0%) | — -21.2K (-100.0%) | 0.00% -0.508 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 11 | CITIGROUP INC | — -5.0K (-100.0%) | — -7.2K (-100.0%) | 0.00% -0.173 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 12 | BANK OF AMERICA CORP /DE/ | — -13.0 (-100.0%) | — -19.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
19.0K
Shares disposed
—
Cash buys
1.00
Cash sales
—
Net activity
+19,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-15 | Bolton Sheryle | Director | P-Purchase | A | Common Stock | 10,000 | 1.04 | 10.4K | 10,000 | D | ↗ |
| 2026-04-01 | Valauri Christina Rizopoulos | Director | P-Purchase | A | Common Stock | 19,000 | 0.95 | 18.0K | 19,000 | D | ↗ |
| 2026-03-18 | Wolf Lisa G | Officer | M-Exempt | D | Restricted Stock Units | 92 | 0.00 | — | 643 | D | ↗ |
| 2026-02-18 | Handley Michael K | Officer | M-Exempt | D | Restricted Stock Units | 8,824 | 0.00 | — | 26,471 | D | ↗ |
| 2025-12-18 | Wolf Lisa G | Officer | F-InKind | D | Common Stock | 302 | 1.87 | 564.74 | 434 | D | ↗ |
| 2025-12-18 | Ernst Jennifer | Director / Officer | M-Exempt | A | Common Stock | 14,706 | 0.00 | — | 37,953 | D | ↗ |
| 2025-09-22 | Ernst Jennifer | Director / Officer | A-Award | A | Common Stock | 22,541 | 0.00 | — | 23,247 | D | ↗ |
| 2025-08-06 | Zikria Dean | Director | A-Award | A | Stock Option (Right to Purchase) | 7,500 | 3.32 | 24.9K | 7,500 | D | ↗ |
| 2025-08-06 | Wolf Lisa G | Officer | A-Award | A | Employee Stock Option (Right to Purchase) | 80,000 | 3.32 | 265.6K | 80,000 | D | ↗ |
| 2025-08-06 | Valauri Christina Rizopoulos | Director | A-Award | A | Stock Option (Right to Purchase) | 7,500 | 3.32 | 24.9K | 7,500 | D | ↗ |
| 2025-08-06 | Handley Michael K | Officer | A-Award | A | Employee Stock Option (Right to Purchase) | 45,000 | 3.32 | 149.4K | 45,000 | D | ↗ |
| 2025-08-06 | Ernst Jennifer | Director / Officer | A-Award | A | Employee Stock Option (Right to Purchase) | 85,000 | 3.32 | 282.2K | 85,000 | D | ↗ |
| 2025-08-06 | Bolton Sheryle | Director | A-Award | A | Stock Option (Right to Purchase) | 12,500 | 3.32 | 41.5K | 12,500 | D | ↗ |
| 2025-02-21 | Handley Michael K | Officer | A-Award | A | Restricted Stock Units | 600,000 | 0.00 | — | 600,000 | D | ↗ |
| 2025-02-18 | Handley Michael K | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-18 | Zikria Dean | Director | A-Award | A | Stock Option (Right to Purchase) | 12,000 | 0.23 | 2.7K | 12,000 | D | ↗ |
| 2024-12-18 | Wolf Lisa G | Officer | A-Award | A | Restricted Stock Units | 25,000 | 0.00 | — | 25,000 | D | ↗ |
| 2024-12-18 | Valauri Christina Rizopoulos | Director | A-Award | A | Stock Option (Right to Purchase) | 12,000 | 0.23 | 2.7K | 12,000 | D | ↗ |
| 2024-12-18 | Gurfein Blake | Officer | A-Award | A | Restricted Stock Units | 225,000 | 0.00 | — | 225,000 | D | ↗ |
| 2024-12-18 | Ernst Jennifer | Director / Officer | A-Award | A | Restricted Stock Units | 500,000 | 0.00 | — | 500,000 | D | ↗ |
| 2024-12-18 | Bolton Sheryle | Director | A-Award | A | Stock Option (Right to Purchase) | 15,000 | 0.23 | 3.4K | 15,000 | D | ↗ |
| 2024-10-01 | Wolf Lisa G | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-10-01 | Bambach Kimberly Ann | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-09-30 | Drexler Karen | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-08-09 | Zikria Dean | Director | A-Award | A | Employee Stock Option (Right to Buy) | 3,000 | 0.41 | 1.2K | 3,000 | — | ↗ |
| 2024-08-09 | Valauri Christina Rizopoulos | Director | A-Award | A | Employee Stock Option (Right to Buy) | 3,000 | 0.41 | 1.2K | 3,000 | — | ↗ |
| 2024-08-09 | Drexler Karen | Director | A-Award | A | Employee Stock Option (Right to Buy) | 3,000 | 0.41 | 1.2K | 3,000 | — | ↗ |
| 2024-08-09 | Bolton Sheryle | Director | A-Award | A | Employee Stock Option (Right to Buy) | 3,000 | 0.41 | 1.2K | 3,000 | — | ↗ |
| 2024-07-01 | Valauri Christina Rizopoulos | Director | — | D | Stock Option (Right to Buy) | 250 | 17.60 | 4.4K | 0 | — | ↗ |
| 2024-03-12 | Gurfein Blake | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 10,000 | 1.34 | 13.4K | 10,000 | — | ↗ |
| 2024-03-12 | Ernst Jennifer | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 32,000 | 1.34 | 42.9K | 32,000 | — | ↗ |
| 2024-03-12 | Bambach Kimberly Ann | Officer | A-Award | A | Common Stock | 7,500 | 0.00 | — | 7,500 | — | ↗ |
| 2023-06-14 | Zikria Dean | Director | A-Award | A | Employee Stock Option (Right to Buy) | 25,000 | 0.09 | 2.3K | 25,000 | — | ↗ |
| 2023-06-14 | Drexler Karen | Director | A-Award | A | Employee Stock Option (Right to Buy) | 25,000 | 0.09 | 2.3K | 25,000 | — | ↗ |
| 2023-06-14 | Bolton Sheryle | Director | A-Award | A | Employee Stock Option (Right to Buy) | 25,000 | 0.09 | 2.3K | 25,000 | — | ↗ |
| 2023-05-08 | Sabia Ryan | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 100,000 | 0.13 | 13.0K | 100,000 | — | ↗ |
| 2023-05-08 | Gurfein Blake | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 100,000 | 0.13 | 13.0K | 100,000 | — | ↗ |
| 2023-05-08 | Ernst Jennifer | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 125,000 | 0.13 | 16.3K | 125,000 | — | ↗ |
| 2023-04-28 | Bambach Kimberly Ann | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-12-31 | Drexler Karen | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-14 | Zikria Dean | Director | A-Award | A | Employee Stock Option (Right to Buy) | 40,000 | 1.75 | 70.0K | 40,000 | — | ↗ |
| 2022-06-14 | Drexler Karen | Director | A-Award | A | Employee Stock Option (Right to Buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-06-14 | Bolton Sheryle | Director | A-Award | A | Employee Stock Option (Right to Buy) | 40,000 | 0.00 | — | 40,000 | — | ↗ |
| 2022-04-01 | Cai Veronica | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 117,880 | 1.61 | 189.8K | 117,880 | — | ↗ |
| 2022-02-04 | Sabia Ryan | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 50,000 | 1.67 | 83.5K | 50,000 | — | ↗ |
| 2022-02-04 | Gurfein Blake | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 35,000 | 1.67 | 58.5K | 35,000 | — | ↗ |
| 2022-02-04 | Ernst Jennifer | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (Right to Buy) | 200,000 | 1.83 | 366.0K | 200,000 | — | ↗ |
| 2021-12-14 | Zikria Dean | Director | A-Award | A | Employee Stock Option (Right to Buy) | 18,000 | 4.59 | 82.6K | 18,000 | — | ↗ |
| 2021-12-14 | Sabia Ryan | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 25,000 | 4.59 | 114.8K | 25,000 | — | ↗ |
| 2021-12-14 | Gurfein Blake | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 82,500 | 4.59 | 378.7K | 82,500 | — | ↗ |
| 2021-12-14 | Drexler Karen | Director | A-Award | A | Employee Stock Option (Right to Buy) | 18,000 | 4.59 | 82.6K | 18,000 | — | ↗ |
| 2021-12-14 | Bolton Sheryle | Director | A-Award | A | Employee Stock Option (Right to Buy) | 18,000 | 4.59 | 82.6K | 18,000 | — | ↗ |
| 2021-11-12 | Ernst Jennifer | Director / Officer / 10% Owner | C-Conversion | A | Common Stock | 26,986 | 0.00 | — | 1,199,877 | — | ↗ |
| 2021-11-10 | Zikria Dean | Director | — | D | Stock Option (Right to Buy) | 6,250 | 1.00 | 6.3K | 0 | — | ↗ |
| 2021-11-10 | Sabia Ryan | Officer | — | D | Stock Option (Right to Buy) | 50,000 | 1.60 | 80.0K | 0 | — | ↗ |
| 2021-11-10 | Gurfein Blake | Officer | — | D | Common Stock | 0 | 0.00 | — | 119,979 | — | ↗ |
| 2021-11-10 | Ernst Jennifer | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,171,500 | — | ↗ |
| 2021-11-10 | Drexler Karen | Director | — | D | Stock Option (Right to Buy) | 6,250 | 1.00 | 6.3K | 0 | — | ↗ |
| 2021-11-10 | Claude John | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,196,000 | — | ↗ |
| 2021-11-10 | Bolton Sheryle | Director | — | D | Stock Option (Right to Buy) | 6,250 | 1.00 | 6.3K | 0 | — | ↗ |
| 2021-11-10 | Benz Briana | Officer | — | D | Common Stock | 0 | 0.00 | — | 112,500 | — | ↗ |
| 2021-03-01 | Ernst Jennifer | Director / Officer / 10% Owner | — | D | Series Seed-2 Convertible Preferred Stock | 1,391 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-1.5K
Shares Outstanding
1.08M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Michael Handley, Chief Executive Officer and Director; Former Chief Operating Officer | 261.3K | — | 305.7K | 135.5K | — | 23.8K | 590.7K | 74.68% | ↗ |
| 2 | 2025 | Jennifer Ernst, Former Chief Executive Officer and Director | 300.0K | — | 68.8K | 255.9K | — | 28.0K | 396.8K | 81.81% | ↗ |
| 3 | 2025 | Lisa Wolf, Chief Financial Officer | 116.4K | — | — | 240.8K | — | 217.6K | 334.0K | 72.10% | ↗ |
| 4 | 2024 | Blake Gurfein, PhD Chief Scientific Officer | 350.0K | 33.0K | 50.9K | 11.3K | — | 52.7K | 486.5K | 12.77% | ↗ |
| 5 | 2024 | Jennifer Ernst, CEO and Director | 275.0K | — | 113.0K | 36.2K | — | 42.5K | 430.5K | 34.65% | ↗ |
| 6 | 2024 | Jennifer Ernst, Former Chief Executive Officer and Director | 275.0K | — | 113.0K | 36.2K | — | 42.5K | 430.5K | 34.65% | ↗ |
| 7 | 2024 | Kimberly Bambach Former Interim Chief Financial Officer | — | — | 10.1K | — | — | 204.3K | 214.3K | 4.69% | ↗ |
| 8 | 2024 | Lisa Wolf, Chief Financial Officer | — | — | 5.7K | — | — | 59.5K | 65.1K | 8.68% | ↗ |
| 9 | 2023 | Blake Gurfein, PhD Chief Scientific Officer | 303.4K | 40.6K | — | 12.3K | — | 48.7K | 392.7K | 3.14% | ↗ |
| 10 | 2023 | Jennifer Ernst, CEO and Director | 275.0K | — | — | 15.4K | — | 38.9K | 313.9K | 4.90% | ↗ |
| 11 | 2023 | Ryan Sabia Former Chief Operating Officer | 229.2K | 10.0K | — | 12.3K | — | 33.8K | 285.2K | 4.32% | ↗ |
| 12 | 2023 | Kimberly Bambach Former Interim Chief Financial Officer | — | — | — | — | — | 197.8K | 197.8K | 0.00% | ↗ |
| 13 | 2022 | Jennifer Ernst, CEO and Director | 275.0K | — | — | 123.3K | — | 20.9K | 419.2K | 29.42% | ↗ |
| 14 | 2022 | Veronica Cai CFO | 243.8K | — | — | 162.0K | — | 1.0K | 406.8K | 39.83% | ↗ |
| 15 | 2022 | Blake Gurfein, PhD Chief Scientific Officer | 275.0K | 50.9K | — | 29.0K | — | 29.9K | 384.9K | 7.54% | ↗ |
| 16 | 2022 | Ryan Sabia Former Chief Operating Officer | 254.2K | 24.8K | — | 41.5K | — | 17.0K | 337.4K | 12.29% | ↗ |
| 17 | 2021 | Blake Gurfein, PhD Chief Scientific Officer | 227.6K | — | — | 184.0K | — | 31.4K | 442.9K | 41.54% | ↗ |
| 18 | 2021 | Briana Benz, CFO | 104.2K | 100.0K | 172.4K | — | — | 18.0K | 376.6K | 45.78% | ↗ |
| 19 | 2021 | Jennifer Ernst, CEO and Director | 218.5K | — | — | — | — | 31.0K | 249.5K | 0.00% | ↗ |
| 20 | 2020 | Blake Gurfein, PhD Chief Scientific Officer | 226.3K | — | — | — | — | 16.3K | 242.5K | 0.00% | ↗ |
| 21 | 2020 | Jennifer Ernst, CEO and Director | 181.1K | — | — | — | — | 16.3K | 197.4K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Lisa G. Wolf | Chief Financial Officer and Principal Financial & Principal Accounting Officer | 334.0K | female |
| Jennifer Ernst | Co-Founder, Chief Executive Officer & Director | 317.5K | female |
| Michael Kevin Handley | CEO & Director | 293.9K | male |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TIVC
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
